The United States of America, As Represented by the Secretary, Department of Health and Human Services

Sequella, Inc.

Other

Clifton E Barry, Iii

Richard Edward Lee

Marina Nikolaevna Protopopova

Richard Allan Slayden

Leo Einck

Elena Bogatcheva

Linda-Gail Bekker

Andrea E DeBarber

Khisimuzi Mdluli

Deborah Crane

Ying Yuan

Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

Compositions and methods for the treatment of infectious diseases

Anti tubercular drug: compositions and methods

The invention relates to the discovery that a putative gene ofwith no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. Sincehas a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854and now termed 'EtaA,' are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.

Methods of diagnosing multidrug resistant tuberculosis

Methods and compositions for treating disease caused by microorganisms, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

Methods of use and compositions for the diagnosis and treatment of infectious disease

The invention relates to the discovery that a putative gene ofwith no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. Sincehas a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854c and now termed 'EtaA,' are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.

This invention provides for novel attenuated strains of and Attenuation is achieved by eliminating or by downregulating the expression of the &agr;-crystallin heat shock protein gene (&ldquo;acr gene&rdquo;). The invention provides for vaccines and methods of vaccinating mammals for protection against Mycobacterium sp. that cause tuberculosis.

Growing community of inventors

Germantown, MD, United States of America

Clifton E Barry, Iii